Variable understanding of QbD among US FDA reviewers is leading to mixed messages and confusion, a consultant said. While the the US Food and Drug Administration (FDA) has stressed Quality-by-Design (QbD) applicants will enjoy regulatory flexibility a survey shows some people are still wary.
